GRACEcast
Expert oncologists provide brief, distilled summaries of the most central issues in cancer management and emerging approaches for patients and caregivers. The Global Resource for Advancing Cancer Education (GRACE) is committed to providing the knowledge that will help enable the general public to be informed participants in their own care. Visit cancerGRACE.org for more info.

Dr. Edward Garon, David Geffen School of Medicine at UCLA, reviews impressive results from the GALAXY-1 trial of the heat shock protein inhibitor ganetespib combined with combined with second line docetaxel in advanced lung adenocarcinoma.

Direct download: GRACEcast-171_Lung-Video_ASCO_2013_Ganetespib_Second_Line.m4v
Category:Lung-Cancer-Video -- posted at: 6:58pm PST

Dr. Edward Garon, David Geffen School of Medicine at UCLA, reviews impressive results from the GALAXY-1 trial of the heat shock protein inhibitor ganetespib combined with combined with second line docetaxel in advanced lung adenocarcinoma.

Direct download: GRACEcast-171_Lung-Audio_ASCO_2013_Ganetespib_Second_Line.mp3
Category:Lung-Cancer-Audio -- posted at: 6:56pm PST

Dr. Edward Garon, David Geffen School of Medicine at UCLA, discusses results in a trial that demonstrated a significant survival benefit with nintedanib combined with second line docetaxel in advanced lung adenocarcinoma.

Direct download: GRACEcast-170_Lung-Video_ASCO_2013_Nintedanib_Second_Line.m4v
Category:Lung-Cancer-Video -- posted at: 4:57pm PST

Dr. Edward Garon, David Geffen School of Medicine at UCLA, discusses results in a trial that demonstrated a significant survival benefit with nintedanib combined with second line docetaxel in advanced lung adenocarcinoma.

Direct download: GRACEcast-170_Lung-Audio_ASCO_2013_Nintedanib_Second_Line.mp3
Category:Lung-Cancer-Audio -- posted at: 4:56pm PST

Dr. Edward Garon, David Geffen School of Medicine at UCLA, describes the exciting developments with LDK-378 and potentially other second generation ALK inhibitors for crizotinib-resistant ALK-positive advanced NSCLC.


Dr. Edward Garon, David Geffen School of Medicine at UCLA, describes the exciting developments with LDK-378 and potentially other second generation ALK inhibitors for crizotinib-resistant ALK-positive advanced NSCLC.


Dr. Edward Garon, David Geffen School of Medicine at UCLA, covers the results and implications of the MADeIT phase III randomized study of preductive biomarkers ERCC1 and RRM1 in advanced NSCLC.

Direct download: GRACEcast-168_Lung-Video_ASCO_2013_MADeIT_ERCC1_RRM1.m4v
Category:Lung-Cancer-Video -- posted at: 11:49am PST

Dr. Edward Garon, David Geffen School of Medicine at UCLA, covers the results and implications of the MADeIT phase III randomized study of preductive biomarkers ERCC1 and RRM1 in advanced NSCLC.

Direct download: GRACEcast-168_Lung-Audio_ASCO_2013_MADeIT_ERCC1_RRM1.mp3
Category:Lung-Cancer-Audio -- posted at: 11:48am PST

Dr. Edward Garon, David Geffen School of Medicine at UCLA, reviews the landmark Biomarkers France study that tested a wide range of molecular markers in NSCLC.

Direct download: GRACEcast-167_Lung-Video_ASCO_2013_Biomarkers_France.m4v
Category:Lung-Cancer-Video -- posted at: 11:47am PST

Dr. Edward Garon, David Geffen School of Medicine at UCLA, reviews the landmark Biomarkers France study that tested a wide range of molecular markers in NSCLC.

Direct download: GRACEcast-167_Lung-Audio_ASCO_2013_Biomarkers_France.mp3
Category:Lung-Cancer-Audio -- posted at: 11:46am PST